Scientists Expose Hidden Gut Toxin Secretly Fueling Diabetes and Liver Damage

New Gut-Microbiome Strategy to Improve Blood Sugar and Liver Health

Illustration showing how trapping gut microbe metabolite D-lactate improves blood sugar and reduces fatty liver inflammation

Gut bacteria metabolite D-lactate affects blood sugar
/ Freepik

The global rise in type 2 diabetes, obesity and fatty liver disease demands innovative treatments. A discovery by Canadian researchers reveals that a lesser-known microbial metabolite—D-lactate—plays a pivotal role in metabolic dysfunction. By “trapping” D-lactate in the gut before absorption, blood sugar levels and liver inflammation in obese mice improved significantly. This breakthrough could open a new therapeutic frontier.

Scientific Background: D-lactate vs L-lactate

L-lactate is well known through the Cori cycle: muscles produce L-lactate, the liver converts it into glucose. However, D-lactate, primarily from gut bacteria, has been less studied. Recent evidence shows D-lactate enters the bloodstream, stimulates the liver to produce excess glucose and triglycerides, and exacerbates metabolic disease—especially in obesity .

Key Findings from the Study

Both obese mice and human subjects with obesity had elevated circulating D-lactate—but not elevated L-lactate
Mice colonized with D-lactate–producing bacteria showed significantly higher blood glucose versus those with L-lactate producers, even when total lactate load was matched .
Stable isotope tracing confirmed D-lactate is metabolized into glucose, lipids, and TCA cycle intermediates more potently than L-lactate .

Gut-Substrate Trap: How It Works

The researchers engineered a safe, biodegradable polymer—composed of specific poly-L-lactide—that binds selectively to D-lactate in the gut lumen. This “trap” prevents absorption, forcing excess D-lactate to be excreted in feces. Administered orally in obese mice, it led to:

Reduced fasting blood glucose and improved insulin sensitivity
Decreased liver fat accumulation and inflammation
Lower fibrosis markers in models of metabolic dysfunction–associated fatty liver disease (MAFLD/MASH) .

Why This Approach Is Groundbreaking

Most current treatments target hormones (e.g. insulin, GLP-1) or directly intervene in liver pathways. This method targets a microbial fuel source before it can impact host metabolism. As Schertzer et al. state: “Instead of targeting hormones or the liver directly, we’re intercepting a microbial fuel source before it can do harm.”

Mechanisms & Immune Effects

D-lactate raised hepatic glycogen, triglycerides and blood glucose more effectively per molecule than L-lactate. It also triggered immune cell activation—Kupffer cells and neutrophils—in the liver. The polymer trap reduced markers like myeloperoxidase and neutrophil elastase, indicating reduced inflammation and fibrosis across all liver lobes .

Limitations and Next Steps

While promising, several caveats remain:

Results are primarily in male mice; human validation is limited to D-lactate measurements in people with obesity .
D-lactate circulates in much lower concentrations than L-lactate, raising questions about mechanism and dose–response dynamics.
The team plans to examine sex differences, quantify microbial vs host D-lactate production in humans, and move toward clinical translation.

Implications for Human Health

If validated in human trials, the D-lactate trap could lead to:

New non-systemic treatments for type 2 diabetes and fatty liver disease
Microbiome-targeted therapies avoiding off-target host effects
Potential for personalized gut-metabolite management based on microbiome profiling

This novel discovery injects microbial metabolism into the well-known Cori cycle and reframes metabolic disease treatment. By sequestering D-lactate before it crosses into the bloodstream, researchers achieved remarkable metabolic improvements in mice. The next phase: rigorous human studies to validate safety, dosing and efficacy. The future of metabolic health treatment may be hiding in plain sight—in the gut microbiome.

ZenHealth Tips